KRYZA David

Fonction : Maitre de conférence

Spécialité :

Génie Pharmaceutique

Bureau : Rock

Téléphone : 04 78 78 29 06

EMail

32 documents

  • Ilaria Andreana, Mathieu Repellin, Flavia Carton, David Kryza, Stephanie Briancon, et al.. Nanomedicine for Gene Delivery and Drug Repurposing in the Treatment of Muscular Dystrophies. Pharmaceutics, MDPI, 2021, 13 (2), pp.278. ⟨10.3390/pharmaceutics13020278⟩. ⟨hal-03151769⟩
  • David Kryza, Frédéric Debordeaux, Laurent Azéma, Aref Hassan, Olivier Paurelle, et al.. Ex Vivo and In Vivo Imaging and Biodistribution of Aptamers Targeting the Human Matrix MetalloProtease-9 in Melanomas. PLoS ONE, Public Library of Science, 2020, 11 (2), pp.e0149387. ⟨10.1371/journal.pone.0149387⟩. ⟨hal-02139130⟩
  • Olga Kochebina, Adrien Halty, Jacqueline Taleb, David Kryza, Marc Janier, et al.. In vivo gadolinium nanoparticle quantification with SPECT/CT. EJNMMI Physics, Springer-Verlag, 2019, 6 (1), ⟨10.1186/s40658-019-0246-y⟩. ⟨hal-02161585⟩
  • Aurélie Moreau, Olivia Febvey, Thomas Mognetti, Didier Frappaz, David Kryza. Contribution of Different Positron Emission Tomography Tracers in Glioma Management: Focus on Glioblastoma. Frontiers in Oncology, Frontiers, 2019, 9, ⟨10.3389/fonc.2019.01134⟩. ⟨hal-02347683⟩
  • Aurélie Moreau, Anne Laure Giraudet, Thomas Mognetti, David Kryza. Retroperitoneal fibrosis in on-going anti-PD-1 immunotherapy detected with [18F]-FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, Springer Verlag (Germany), 2019, ⟨10.1007/s00259-019-04352-1⟩. ⟨hal-02139023⟩
  • A.L. Giraudet, Aurélie Moreau, David Kryza. The French experience of PSMA PET for the diagnosis of biological recurrence of prostate cancer. Médecine Nucléaire, Elsevier/Masson, 2019, ⟨10.1016/j.mednuc.2019.04.004⟩. ⟨hal-02139029⟩
  • Anne-Laure Giraudet, Philippe Cassier, Chicaco Iwao-Fukukawa, Gwenaelle Garin, Jean-Noël Badel, et al.. A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. BMC Cancer, BioMed Central, 2018, 18 (1), ⟨10.1186/s12885-018-4544-x⟩. ⟨hal-01840634⟩
  • Gabriel de Crozals, David Kryza, Gloria Jiménez Sánchez, Stéphane Roux, Doriane Mathé, et al.. Granulocyte Colony-Stimulating Factor Nanocarriers for Stimulation of the Immune System (Part I): Synthesis and Biodistribution Studies. Bioconjugate Chemistry, American Chemical Society, 2018, 29 (3), pp.795 - 803. ⟨10.1021/acs.bioconjchem.7b00605⟩. ⟨hal-01767382⟩
  • David Kryza, Gabriel de Crozals, Doriane Mathé, Jacqueline Taleb Sidi-Boumedine, Marc Janier, et al.. Granulocyte-Colony Stimulating Factor Nanocarriers for Stimulation of the Immune System (Part II): Dose-Dependent Biodistribution and In Vivo Antitumor Efficacy in Combination with Rituximab. Bioconjugate Chemistry, American Chemical Society, 2018, 29 (3), pp.804 - 812. ⟨10.1021/acs.bioconjchem.7b00606⟩. ⟨hal-01767371⟩
  • David Kryza, Olga Kochebina, Adrien Halty, Jacqueline Taleb, David Kryza T, et al.. Quantification of Gd-Nanoparticles Concentration with SPECT and Spectral Photon Counting CT. Conference: 2017 IEEE Nuclear Science Symposium and Medical Imaging Conference, Oct 2017, Atlanta, United States. pp.1-5. ⟨hal-02139139⟩